Annika Ã–hrfelt

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1888994/publications.pdf

Version: 2024-02-01

41 papers	4,568 citations	186265 28 h-index	315739 38 g-index
41 all docs	41 docs citations	41 times ranked	6521 citing authors

#	Article	IF	Citations
1	CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurology, The, 2016, 15, 673-684.	10.2	1,413
2	Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders. Archives of Neurology, 2012, 69, 1445.	4.5	407
3	Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 1180-1190.	0.8	254
4	Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2016, 11, 3.	10.8	236
5	SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2014, 9, 53.	10.8	216
6	Cerebrospinal fluid Î±-synuclein in neurodegenerative disordersâ€”A marker of synapse loss?. Neuroscience Letters, 2009, 450, 332-335.	2.1	194
7	CSF biomarkers and clinical progression of Parkinson disease. Neurology, 2015, 84, 57-63.	1.1	178
8	Levels of cerebrospinal fluid Î±-synuclein oligomers are increased in Parkinsonâ€™s disease with dementia and dementia with Lewy bodies compared to Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2014, 6, 25.	6.2	169
9	Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease. JAMA Neurology, 2015, 72, 1175.	9.0	148
10	<scp>L</scp>ongitudinal <scp>M</scp>easurements of <scp>C</scp>erebrospinal <scp>F</scp>luid <scp>B</scp>iomarkers in <scp>P</scp>arkinson's <scp>D</scp>isease. Movement Disorders, 2016, 31, 898-905.	3.9	136
11	The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2016, 8, 41.	6.2	121
12	Identification of Novel Î±-Synuclein Isoforms in Human Brain Tissue by using an Online NanoLC-ESI-FTICR-MS Method. Neurochemical Research, 2011, 36, 2029-2042.	3.3	99
13	Metabolite and Peptide Levels in Plasma and CSF Differentiating Healthy Controls from Patients with Newly Diagnosed Parkinson's Disease. Journal of Parkinson's Disease, 2014, 4, 549-560.	2.8	99
14	An online nanoâ€ŁCâ€ESIâ€FTICRâ€MS method for comprehensive characterization of endogenous fragments from amyloid Î² and amyloid precursor protein in human and cat cerebrospinal fluid. Journal of Mass Spectrometry, 2012, 47, 591-603.	1.6	78
15	Transient Inflammation in Neurogenic Regions after Irradiation of the Developing Brain. Radiation Research, 2009, 171, 66-76.	1.5	77
16	Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone. Multiple Sclerosis Journal, 2016, 22, 1587-1595.	3.0	73
17	The Gothenburg MCI study: Design and distribution of Alzheimerâ€™s disease and subcortical vascular disease diagnoses from baseline to 6-year follow-up. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 114-131.	4.3	67
18	Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimerâ€™s and Parkinsonâ€™s disease. Alzheimer's Research and Therapy, 2019, 11, 82.	6.2	51

#	Article	IF	Citations
19	Mass Spectrometric Analysis of Lewy Body-Enriched Î±-Synuclein in Parkinsonâ€™s Disease. Journal of Proteome Research, 2019, 18, 2109-2120.	3.7	49
20	Evaluation of the Cerebrospinal Fluid Amyloid-Î²₁₋₄₂/Amyloid-Î²₁₋₄₀ Ratio Measured by Alpha-LISA to Distinguish Alzheimer's Disease from Other Dementia Disorders. Dementia and Geriatric Cognitive Disorders, 2013, 36, 99-110.	1.5	45
21	Soluble amyloid precursor protein Î± and Î² in CSF in Alzheimer's disease. Brain Research, 2013, 1513, 117-126.	2.2	43
22	Alzheimerâ€™s diseaseâ€”subcortical vascular disease spectrum in a hospital-based setting: Overview of results from the Gothenburg MCI and dementia studies. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 95-113.	4.3	42
23	Explorative and targeted neuroproteomics in Alzheimer's disease. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2015, 1854, 769-778.	2.3	41
24	Identification of novel N-terminal fragments of amyloid precursor protein in cerebrospinal fluid. Experimental Neurology, 2010, 223, 351-358.	4.1	37
25	Screening for New Biomarkers for Subcortical Vascular Dementia and Alzheimerâ€™s Disease. Dementia and Geriatric Cognitive Disorders Extra, 2011, 1, 31-42.	1.3	35
26	Increased Cerebrospinal Fluid Levels of Ubiquitin Carboxyl-Terminal Hydrolase L1 in Patients with Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 2016, 6, 283-294.	1.3	33
27	Evolution of cerebrospinal fluid total Î±-synuclein in Parkinson's disease. Parkinsonism and Related Disorders, 2018, 49, 4-8.	2.2	31
28	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. Neurobiology of Aging, 2015, 36, 2587-2596.	3.1	30
29	Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders. Proteomics - Clinical Applications, 2017, 11, 1700100.	1.6	28
30	Targeting Synaptic Pathology with a Novel Affinity Mass Spectrometry Approach. Molecular and Cellular Proteomics, 2014, 13, 2584-2592.	3.8	26
31	Characteristic clinical presentation and CSF biomarker pattern in cerebral small vessel disease. Journal of the Neurological Sciences, 2012, 322, 192-196.	0.6	25
32	A Novel ELISA for the Measurement of Cerebrospinal Fluid SNAP-25 in Patients with Alzheimerâ€™s Disease. Neuroscience, 2019, 420, 136-144.	2.3	25
33	Targeting LAMP2 in human cerebrospinal fluid with a combination of immunopurification and high resolution parallel reaction monitoring mass spectrometry. Clinical Proteomics, 2016, 13, 4.	2.1	22
34	Expression and secretion of synaptic proteins during stem cell differentiation to cortical neurons. Neurochemistry International, 2018, 121, 38-49.	3.8	20
35	Full-length and C-terminal neurogranin in Alzheimerâ€™s disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays. Alzheimer's Research and Therapy, 2020, 12, 168.	6.2	7
36	Validation of a new assay for Î±-synuclein detection in cerebrospinal fluid. Clinical Chemistry and Laboratory Medicine, 2017, 55, 254-260.	2.3	6

#	Article	IF	Citations
37	Detection of Î±-Synuclein in Biological Samples Using Mass Spectrometry. Methods in Molecular Biology, 2019, 1948, 209-220.	0.9	4
38	Expression of Pisum sativum SAD polypeptides in production hosts and in planta: Tetrameric organization of the protein. Protein Expression and Purification, 2009, 63, 18-25.	1.3	3
39	P2-110: ELEVATED CEREBROSPINAL FLUID LEVELS OF NEUROGRANIN IN ALZHEIMER'S DISEASE. , 2014, 10, P511-P511.		0
40	P2-101: EVALUATION OF THE PRESYNAPTIC PROTEIN SNAP-25 AS A NOVEL CEREBROSPINAL FLUID MARKER FOR SYNAPTIC PATHOLOGY IN ALZHEIMER'S DISEASE. , 2014, 10, P508-P508.		0
41	[P1â€“221]: EXPRESSION AND SECRETION OF SYNAPTIC PROTEINS DURING DIFFERENTIATION OF PLURIPOTENT STEM CELLS TO CORTICAL NEURONS. Alzheimer's and Dementia, 2017, 13, P328.	0.8	0